A Randomized, Controlled Pilot Trial to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Treating Interstitial Lung Disease Associated With the Anti-synthetase Syndrome
Phase of Trial: Phase II
Latest Information Update: 12 Oct 2017
At a glance
- Drugs Abatacept (Primary)
- Indications Interstitial lung diseases; Myositis
- Focus Proof of concept; Therapeutic Use
- Acronyms ATtackMy-ILD
- 09 Oct 2017 Status changed from not yet recruiting to recruiting.
- 08 Sep 2017 Planned initiation date changed from 30 Aug 2017 to 30 Sep 2017.
- 07 Aug 2017 Planned initiation date changed from 1 Aug 2017 to 30 Aug 2017.